Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Symptomatic Dermographism Clear all

Recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402

View directory record Official record

Conditions: Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Interventions: Barzolvolimab, Matching Placebo; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 21, 2026, 7:13 PM EDT

Terminated No phase listed Observational

The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism

NCT01008592

View directory record Official record

Conditions: Rhinitis, Urticaria
Interventions: levocetirizine or placebo; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 60 Years

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Source: ClinicalTrials.gov public record

Updated Feb 27, 2017 · Synced May 21, 2026, 7:13 PM EDT

Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

NCT05024058

View directory record Official record

Conditions: Chronic Inducible Urticaria
Interventions: Ligelizumab, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older

Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Evansville, Indiana • North Charleston, South Carolina • El Paso, Texas + 1 more

Source: ClinicalTrials.gov public record

Updated Jun 17, 2024 · Synced May 21, 2026, 7:13 PM EDT

Recruiting Phase 2 Interventional

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405

View directory record Official record

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: BLU-808, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older

Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 23 more

Source: ClinicalTrials.gov public record

Updated Feb 16, 2026 · Synced May 21, 2026, 7:13 PM EDT

Completed No phase listed Observational

Pathogenesis of Physical Induced Urticarial Syndromes

NCT00887939

View directory record Official record

Conditions: Hypersensitivity, Immediate, Autoinflammatory Syndromes, Physical Urticaria, Familial Cold Autoinflammatory Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 90 Years

Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 29, 2026 · Synced May 21, 2026, 7:13 PM EDT

Recruiting Phase 2 Interventional

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

NCT06865651

View directory record Official record

Conditions: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years

Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: North Miami Beach, Florida • Glenview, Illinois

Source: ClinicalTrials.gov public record

Updated May 3, 2026 · Synced May 21, 2026, 7:13 PM EDT